{"disease":{"id":"cutaneous-lupus","name":"Cutaneous Lupus","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":4},"drugs":{"marketed":[],"pipeline":[{"drug_id":"tofacitinib-xr","indication_name":"Cutaneous Lupus","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofacitinib XR","generic_name":"tofacitinib-xr","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"JAK1, JAK2, JAK3, TYK2","drug_class":"JAK inhibitor","quality_score":50,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06927219","title":"Research Accelerated by You Lupus Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Lupus Foundation of America","has_results":false},{"nct_id":"NCT03276923","title":"Maternal Autoimmune Disease Research Alliance (MADRA) Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05928169","title":"Determinants of Chronic Inflammatory Skin Disease Trajectories","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital Schleswig-Holstein","has_results":false},{"nct_id":"NCT06599411","title":"Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05531565","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06044337","title":"A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":322,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06015737","title":"A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":302,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02847598","title":"Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06506214","title":"Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus","phase":"","overall_status":"RECRUITING","enrollment_count":233,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT07332481","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT07355218","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT06965244","title":"Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03122431","title":"Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":true},{"nct_id":"NCT04781816","title":"Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT07408908","title":"Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Xiamen Amoytop Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT01300208","title":"To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03134222","title":"Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03260166","title":"Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT06875960","title":"A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07306585","title":"The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"HC Biopharma Inc.","has_results":false},{"nct_id":"NCT03817424","title":"A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04647708","title":"Study of M5049 in CLE and SLE Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT02656082","title":"Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT05629208","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT03288324","title":"Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":true},{"nct_id":"NCT05048238","title":"Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04809623","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03639857","title":"Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"David Weinstein","has_results":true},{"nct_id":"NCT02428309","title":"Autologous Polyclonal Tregs for Lupus","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}